What is it about?

Ridker, who is Eugene Braunwald Professor of Medicine at Harvard University stunned audiences at the 2017 ESC Congess with findings from CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study).

Featured Image

Why is it important?

Shock waves from the CANTOS trial are likely to ripple out for many years to come. In his own words, Ridker, the principal investigator of CANTOS and many other game-changing clinical trials talks about the background to his work and looks to the future.


Very few can be involved in this sort of ground-breaking research, but reading Paul Ridker's account of his work is the next best thing. Prepare to be inspired and stunned in equal measure.

Judith Ozkan

Read the Original

This page is a summary of: Paul Ridker MD, European Heart Journal, December 2017, Oxford University Press (OUP),
DOI: 10.1093/eurheartj/ehx724.
You can read the full text:




The following have contributed to this page